Skip to Content

Posts tagged with "Alzheimer’s Disease"

  • Alzheimer's Disease

    Lilly Goes All In on Solanezumab

    So Eli Lilly is going to double down on solanezumab, their antibody treatment for Alzheimer’s that did not show impressive results in earlier trials. The company is going into an even bigger Phase III, with a more carefully selected patient population, in hopes of showing a benefit. Yikes. On one level, I sort of admire… Read More
  • Alzheimer's Disease

    A Beta-Secretase Inhibitor Hits the Skids in Alzheimer’s

    The brutal drumbeat of Alzheimer’s clinical failure continues at Eli Lilly. After the Phase III failure of their gamma-secretase inhibitor semagacestat, and a delusional attempt to pretend that the anti-amyloid antibody solanezumab succeeded, now comes word that the company has halted studies of a beta-secretase inhibitor. This one wasn’… Read More
  • Alzheimer's Disease

    Update on Bexarotene for Alzheimer’s

    Here’s a follow-up on the news that bexarotene might be useful for Alzheimer’s. Unfortunately, what seems to be happening is what happens almost every time that the word “Alzheimer’s” is mentioned along with a small molecule. As Nature reports here, further studies are delivering puzzling results. The original work, fr… Read More
  • Alzheimer's Disease

    The FDA’s New Alzheimer’s Guidance: Wonder or Blunder?

    You can get either answer, depending on whom you ask. Last month, the agency unveiled new guidelines for developing Alzheimer’s therapies. They’re trying to deal with the difficulty of showing actual cognitive improvement in more advanced patients, while at the same time figuring out how to evaluate therapies in early-stage patients who… Read More
  • Alzheimer's Disease

    TauRx’s Funding Is Odd

    I still get inquiries about TauRx and their work on Alzheimer’s. There’s an awful lot of pent-up demand in that field, and it’s getting worse every year. The latest is that the company has ten million more dollars in a follow-on investment option from the Dundee Corporation of Toronto. Who they? That’s what I wondered… Read More
  • Alzheimer's Disease

    CETP, Alzheimer’s, Monty Hall, and Roulette. And Goats.

    CETP, now there’s a drug target that has incinerated a lot of money over the years. Here’s a roundup of compounds I posted on back last summer, with links to their brutal development histories. I wondered here about what’s going to happen with this class of compounds: will one ever make it as a drug?… Read More
  • Alzheimer's Disease

    Eli Lilly’s Brave Alzheimer’s Talk

    I’m a bit baffled by Eli Lilly’s strategy on Alzheimer’s. Not the scientific side of it – they’re going strongly after the amyloid hypothesis, with secretase inhibitors and antibody therapies, and if I were committed to the amyloid hypothesis, that’s probably what I’d be doing, too. It is, after all, the st… Read More
  • Alzheimer's Disease

    Merck Presses Ahead on Alzheimer’s:

    One Alzheimer’s compound recently died off in the clinic – Bristol-Myers Squibb’s avagacestat, a gamma-secretase inhibitor, has been pulled from trials. The compound “did not establish a profile that supported advancement” to Phase III, says the company. Gamma-secretase has been a troubled area for some time, highlight… Read More
  • Alzheimer's Disease

    TauRx Goes Into Phase III For Alzheimer’s

    I can’t even count the number of e-mails I’ve gotten over the last few years asking about TauRx and their Alzheimer’s program, which made a big splash back in 2008. Finally, there’s some news to report. The company is starting Phase III clinical trials, and has announced new financing to see these through. The company… Read More
  • Alzheimer's Disease

    And Since We’re Talking About Insider Trading

    Here’s something from just this morning, a whopping large case on illegal trading in Wyeth and Elan stock. This one involves a hedge fund manager, Mathew Martoma, and (quite disturbingly), Dr. Sidney Gilman of the University of Michigan, who was the lead investigator on a very large bapineuzumab trial for Alzheimer’s. His conduct appear… Read More
...678...